Sort
4,870 grants matching “glp 1”
Development of an oral therapeutic to mimic the anti-diabetic effects of gastric bypass surgery
$999,864Jerzy Szewczyk · Biokier, Inc. · R44 · FY2019 · DK
ELD607 Orai1 Antagonist Increases Bacterial Clearance from the Lung
$999,840Robert Tarran · Eldec Pharmaceuticals, Inc. · R42 · FY2021 · AI
Development of a novel therapeutic for the treatment of diabetic nephropathy and renal fibrosis
$999,838Fabio Cohen Tucci · Epigen Biosciences, Inc. · R44 · FY2020 · DK
GMP manufacturing and IND Filing of IN-002, a potent inhaled muco-trapping antibody therapy for Respiratory Syncytial Virus
$999,810Jeff T Hutchins · Inhalon Biopharma, Inc. · SB1 · FY2023 · AI
Lipid Receptor GPR31 as a Target for Anti-Thrombotic and Stroke Therapy
$999,799Athan Kuliopulos · Oasis Pharmaceuticals · R42 · FY2023 · HL
Lipid Receptor GPR31 as a Target for Anti-Thrombotic and Stroke Therapy
$999,799Athan Kuliopulos · Oasis Pharmaceuticals · R42 · FY2024 · HL
Development of an oral therapeutic to mimic the anti-diabetic effects of gastric bypass surgery
$999,795Jerzy Szewczyk · Biokier, Inc. · R44 · FY2020 · DK
IND-enabling studies of D6PV- a novel ApoC-II peptide mimetic therapeutic
$999,776Matt Devalaraja · Protean Bio Inc. · R44 · FY2025 · DK
Development of MRS-2541, a methionyl-tRNA synthetase inhibitor, for Gram positive bacterial infections.
$999,765Elke Lipka · Tsrl, Inc. · R44 · FY2025 · AI
An inhaled PDGF receptor inhibitor for the treatment of pulmonary arterial hypertension
$999,751Lawrence S. Zisman · Pulmokine, Inc. · R44 · FY2017 · HL
Development of an oral therapeutic to mimic the anti-diabetic effects of gastric bypass surgery
$999,710Jerzy Szewczyk · Biokier, Inc. · R44 · FY2021 · DK
Humanized Antibody Therapeutic to Improve Cardiac Function Following Myocardial I
$999,700Walter Newman · Decimmune Therapeutics, Inc · R44 · FY2014 · HL
Development of TP-317 in Ulcerative Colitis
$999,696John Parkinson · Thetis Pharmaceuticals, Llc · R44 · FY2025 · DK
Development of Chemistry, Manufacturing, and Control Standards for PGC and PGC-dANP
$999,661Gerardo M. Castillo · Pharmain Corporation · R44 · FY2017 · HL
Development of TP-317 in Ulcerative Colitis
$999,624John Parkinson · Thetis Pharmaceuticals, Llc · R44 · FY2024 · DK
Development of Chemistry, Manufacturing, and Control Standards for PGC and PGC-dANP
$999,596Gerardo M. Castillo · Pharmain Corporation · R44 · FY2018 · HL
Preclinical development of teixobactin, a new antibiotic
$999,567Dallas Hughes · Novobiotic Pharmaceuticals, Llc · R44 · FY2020 · AI
Factor XI inhibitor for thrombosis
$999,525Erik Ian Tucker · Aronora, Inc. · R44 · FY2018 · HL
Factor XI inhibitor for thrombosis
$999,525Erik Ian Tucker · Aronora, Inc. · R44 · FY2019 · HL
Sustained release gel enabling one-stage treatment of prosthetic joint infection
$999,516Derek James Overstreet · Sonoran Biosciences, Inc. · R44 · FY2020 · AI
Development of a small molecule activator of integrin cell adhesion to enhance therapeutic responses to checkpoint blockade in cancer
$999,501Upendra Marathi · 7 Hills Pharma, Llc · R42 · FY2018 · CA
Development of a novel therapeutic for the treatment of diabetic nephropathy and renal fibrosis
$999,500Fabio Cohen Tucci · Epigen Biosciences, Inc. · R44 · FY2018 · DK
An inhaled PDGF receptor inhibitor for the treatment of pulmonary arterial hypertension
$999,482Lawrence S. Zisman · Pulmokine, Inc. · R44 · FY2016 · HL
Selection and preclinical development of a bacteria-targeting, non-antibiotic lead candidate to improve cancer chemotherapy outcomes
$999,480Ward Peterson · Symberix, Inc. · R44 · FY2020 · CA
Therapeutic Antibody for CMV
$999,425Lawrence Michael Kauvar · Trellis Bioscience, Inc. · SB1 · FY2019 · AI